EcoDrugPlus

40s Ribosomal Protein S4, X Isoform

Ensembl ID : ENSOMYG00000036395
Gene Symbol: RS4X
2 Cross references
488 Possible Orthologues:

40s Ribosomal Protein S5

Ensembl ID : ENSOMYG00000038712
Gene Symbol: RS5
2 Cross references
258 Possible Orthologues:

5'-Nucleotidase, Ecto (Cd73)

Ensembl ID : ENSOMYG00000030334
Gene Symbol: NT5E
1 Cross references
207 Possible Orthologues:

5'-Nucleotidase, Ecto (Cd73)

Ensembl ID : ENSOMYG00000000596
Gene Symbol: NT5E
1 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 1a B

Ensembl ID : ENSOMYG00000032055
Gene Symbol: HTR1AB
1 Cross references
137 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2b, G Protein-Coupled

Ensembl ID : ENSOMYG00000000960
Gene Symbol: HTR2B
1 Cross references
196 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2b, G Protein-Coupled

Ensembl ID : ENSOMYG00000003380
Gene Symbol: HTR2B
1 Cross references
196 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled-Like 1

Ensembl ID : ENSOMYG00000027324
Gene Symbol: HTR2CL1
1 Cross references
195 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled-Like 1

Ensembl ID : ENSOMYG00000068997
Gene Symbol: HTR2CL1
1 Cross references
195 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSOMYG00000030129
Gene Symbol: HTR1B
1 Cross references
176 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSOMYG00000023837
Gene Symbol: HTR1B
1 Cross references
176 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSOMYG00000000488
Gene Symbol: HTR1B
1 Cross references
176 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).